Investor Information Materials
Artelo Biosciences, Inc.
(Nasdaq: ARTL)
Recent Price: $1.16
Shares O/S: 23 Million
Approx. MktCap: $26.6 Million
There is no FDA-approved product for cancer anorexia, yet it affects more than 60 percent of advanced cancer patients. Three to five of every 10 diagnosed cancer patients die of anorexia, not the cancer. Artelo’s candidate will report early data 4Q21, and topline efficacy data in 1H22.

No less interesting is how Artelo came upon this drug candidate and the reasons why its developer, AstraZeneca, gave up on it.

Wall Street coverage by Ladenburg Thalmann and Maxim Group.

ARTL At A Glance

Little publicized details about cancer anorexia spotlight large unmet need – Artelo’s initial data is due before year-end.

Artelo Bioscieces
Corporate Presentation

Slide Presentation

Visit Artelo Biosciences's website

Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company’s intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company’s product candidates and sufficiency of the company’s cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company’s Annual Report on Form 10-K and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company’s research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by subject company as an investor relations advisor, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.

Call 212 926-1733